{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,16]],"date-time":"2025-09-16T21:20:25Z","timestamp":1758057625494,"version":"3.44.0"},"reference-count":58,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T00:00:00Z","timestamp":1753833600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T00:00:00Z","timestamp":1753833600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Diagn Ther"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1007\/s40291-025-00798-2","type":"journal-article","created":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T23:28:11Z","timestamp":1753918091000},"page":"563-569","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["The Future of Chemogenetics for the Treatment of Spasticity"],"prefix":"10.1007","volume":"29","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2710-2464","authenticated-orcid":false,"given":"Kelly","family":"Poth","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-5514-9945","authenticated-orcid":false,"given":"Roy Raheb","family":"Khelo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7591-7417","authenticated-orcid":false,"given":"Anthony","family":"Donsante","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7271-3953","authenticated-orcid":false,"given":"Nicholas M.","family":"Boulis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,7,30]]},"reference":[{"issue":"2","key":"798_CR1","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1093\/neuros\/nyab147","volume":"89","author":"KM Poth","year":"2021","unstructured":"Poth KM, Texakalidis P, Boulis NM. Chemogenetics: beyond lesions and electrodes. Neurosurgery. 2021;89(2):185\u201395. https:\/\/doi.org\/10.1093\/neuros\/nyab147.","journal-title":"Neurosurgery"},{"key":"798_CR2","doi-asserted-by":"publisher","DOI":"10.1155\/2014\/354906","volume":"2014","author":"C Trompetto","year":"2014","unstructured":"Trompetto C, et al. Pathophysiology of spasticity: implications for neurorehabilitation. Biomed Res Int. 2014;2014: 354906. https:\/\/doi.org\/10.1155\/2014\/354906.","journal-title":"Biomed Res Int"},{"key":"798_CR3","doi-asserted-by":"publisher","first-page":"1845","DOI":"10.1055\/b000000751","volume-title":"Greenberg's handbook of neurosurgery","author":"MS Greenberg","year":"2023","unstructured":"Greenberg MS. Functional neurosurgery and stereotactic neurosurgery. In: Greenberg MS, editor. Greenberg\u2019s handbook of neurosurgery. New York: Thieme; 2023. p. 1845\u201353."},{"key":"798_CR4","first-page":"540","volume":"192","author":"B Ashworth","year":"1964","unstructured":"Ashworth B. Preliminary trial of carisoprodol in multiple sclerosis. Practitioner. 1964;192:540\u20132.","journal-title":"Practitioner"},{"key":"798_CR5","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1016\/B978-0-323-98817-9.00010-7","volume":"196","author":"J Marsden","year":"2023","unstructured":"Marsden J, Stevenson V, Jarrett L. Treatment of spasticity. Handb Clin Neurol. 2023;196:497\u2013521. https:\/\/doi.org\/10.1016\/B978-0-323-98817-9.00010-7.","journal-title":"Handb Clin Neurol"},{"issue":"1\u20132","key":"798_CR6","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1615\/CritRevPhysRehabilMed.2013007945","volume":"25","author":"E Chang","year":"2013","unstructured":"Chang E, et al. A review of spasticity treatments: pharmacological and interventional approaches. Crit Rev Phys Rehabil Med. 2013;25(1\u20132):11\u201322. https:\/\/doi.org\/10.1615\/CritRevPhysRehabilMed.2013007945.","journal-title":"Crit Rev Phys Rehabil Med"},{"key":"798_CR7","unstructured":"Ghanavatian S, Derian A. Baclofen. In: Disclosure: Armen Derian declares no relevant financial relationships with ineligible companies. Treasure Island (FL) ineligible companies: StatPearls. 2025."},{"issue":"1","key":"798_CR8","doi-asserted-by":"publisher","first-page":"e48","DOI":"10.1212\/WNL.0000000000006688","volume":"92","author":"P Albrecht","year":"2019","unstructured":"Albrecht P, et al. High prevalence of neutralizing antibodies after long-term botulinum neurotoxin therapy. Neurology. 2019;92(1):e48\u201354. https:\/\/doi.org\/10.1212\/WNL.0000000000006688.","journal-title":"Neurology"},{"issue":"13","key":"798_CR9","doi-asserted-by":"publisher","first-page":"1775","DOI":"10.1002\/mds.25582","volume":"28","author":"J Ramirez-Castaneda","year":"2013","unstructured":"Ramirez-Castaneda J, et al. Diffusion, spread, and migration of botulinum toxin. Mov Disord. 2013;28(13):1775\u201383. https:\/\/doi.org\/10.1002\/mds.25582.","journal-title":"Mov Disord"},{"issue":"3","key":"798_CR10","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1007\/s00702-021-02312-4","volume":"128","author":"D Dressler","year":"2021","unstructured":"Dressler D, et al. Consensus guidelines for botulinum toxin therapy: general algorithms and dosing tables for dystonia and spasticity. J Neural Transm (Vienna). 2021;128(3):321\u201335. https:\/\/doi.org\/10.1007\/s00702-021-02312-4.","journal-title":"J Neural Transm (Vienna)"},{"issue":"6","key":"798_CR11","doi-asserted-by":"publisher","first-page":"659","DOI":"10.3171\/2024.6.PEDS23360","volume":"34","author":"MV Ryan","year":"2024","unstructured":"Ryan MV, et al. Complications of intrathecal baclofen therapy in children and young adults. J Neurosurg Pediatr. 2024;34(6):659\u201370. https:\/\/doi.org\/10.3171\/2024.6.PEDS23360.","journal-title":"J Neurosurg Pediatr"},{"issue":"3","key":"798_CR12","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1136\/practneurol-2021-003184","volume":"22","author":"MS Balaratnam","year":"2022","unstructured":"Balaratnam MS, Stevenson VL. Intrathecal baclofen pumps: what the neurologist needs to know. Pract Neurol. 2022;22(3):241\u20136. https:\/\/doi.org\/10.1136\/practneurol-2021-003184.","journal-title":"Pract Neurol"},{"issue":"10","key":"798_CR13","doi-asserted-by":"publisher","first-page":"1669","DOI":"10.1016\/j.clinph.2009.12.041","volume":"121","author":"SM ElBasiouny","year":"2010","unstructured":"ElBasiouny SM, Schuster JE, Heckman CJ. Persistent inward currents in spinal motoneurons: important for normal function but potentially harmful after spinal cord injury and in amyotrophic lateral sclerosis. Clin Neurophysiol. 2010;121(10):1669\u201379. https:\/\/doi.org\/10.1016\/j.clinph.2009.12.041.","journal-title":"Clin Neurophysiol"},{"issue":"4","key":"798_CR14","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1016\/j.ijge.2018.05.005","volume":"12","author":"C-L Kuo","year":"2018","unstructured":"Kuo C-L, Hu G-C. Post-stroke spasticity: a review of epidemiology, pathophysiology, and treatments. Int J Gerontol. 2018;12(4):280\u20134. https:\/\/doi.org\/10.1016\/j.ijge.2018.05.005.","journal-title":"Int J Gerontol"},{"issue":"3","key":"798_CR15","doi-asserted-by":"publisher","first-page":"2107","DOI":"10.1152\/jn.1996.76.3.2107","volume":"76","author":"RH Lee","year":"1996","unstructured":"Lee RH, Heckman CJ. Influence of voltage-sensitive dendritic conductances on bistable firing and effective synaptic current in cat spinal motoneurons in vivo. J Neurophysiol. 1996;76(3):2107\u201310. https:\/\/doi.org\/10.1152\/jn.1996.76.3.2107.","journal-title":"J Neurophysiol"},{"issue":"2","key":"798_CR16","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1152\/jn.1998.80.2.572","volume":"80","author":"RH Lee","year":"1998","unstructured":"Lee RH, Heckman CJ. Bistability in spinal motoneurons in vivo: systematic variations in rhythmic firing patterns. J Neurophysiol. 1998;80(2):572\u201382. https:\/\/doi.org\/10.1152\/jn.1998.80.2.572.","journal-title":"J Neurophysiol"},{"issue":"6","key":"798_CR17","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1038\/nm.2160","volume":"16","author":"KC Murray","year":"2010","unstructured":"Murray KC, et al. Recovery of motoneuron and locomotor function after spinal cord injury depends on constitutive activity in 5-HT2C receptors. Nat Med. 2010;16(6):694\u2013700. https:\/\/doi.org\/10.1038\/nm.2160.","journal-title":"Nat Med"},{"issue":"4","key":"798_CR18","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1038\/nm.4061","volume":"22","author":"C Brocard","year":"2016","unstructured":"Brocard C, et al. Cleavage of Na(+) channels by calpain increases persistent Na(+) current and promotes spasticity after spinal cord injury. Nat Med. 2016;22(4):404\u201311. https:\/\/doi.org\/10.1038\/nm.4061.","journal-title":"Nat Med"},{"issue":"2","key":"798_CR19","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1016\/j.expneurol.2005.10.005","volume":"197","author":"P Kitzman","year":"2006","unstructured":"Kitzman P. Changes in vesicular glutamate transporter 2, vesicular GABA transporter and vesicular acetylcholine transporter labeling of sacrocaudal motoneurons in the spastic rat. Exp Neurol. 2006;197(2):407\u201319. https:\/\/doi.org\/10.1016\/j.expneurol.2005.10.005.","journal-title":"Exp Neurol"},{"issue":"3","key":"798_CR20","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1038\/nm.2107","volume":"16","author":"P Boulenguez","year":"2010","unstructured":"Boulenguez P, et al. Down-regulation of the potassium-chloride cotransporter KCC2 contributes to spasticity after spinal cord injury. Nat Med. 2010;16(3):302\u20137. https:\/\/doi.org\/10.1038\/nm.2107.","journal-title":"Nat Med"},{"issue":"6","key":"798_CR21","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1016\/j.rehab.2018.04.004","volume":"62","author":"KS Sunnerhagen","year":"2019","unstructured":"Sunnerhagen KS, Opheim A, AltMurphy M. Onset, time course and prediction of spasticity after stroke or traumatic brain injury. Ann Phys Rehabil Med. 2019;62(6):431\u20134. https:\/\/doi.org\/10.1016\/j.rehab.2018.04.004.","journal-title":"Ann Phys Rehabil Med"},{"key":"798_CR22","doi-asserted-by":"publisher","first-page":"468","DOI":"10.3389\/fneur.2019.00468","volume":"10","author":"S Li","year":"2019","unstructured":"Li S, et al. A unifying pathophysiological account for post-stroke spasticity and disordered motor control. Front Neurol. 2019;10:468. https:\/\/doi.org\/10.3389\/fneur.2019.00468.","journal-title":"Front Neurol"},{"issue":"5","key":"798_CR23","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1002\/mus.20284","volume":"31","author":"JM Gracies","year":"2005","unstructured":"Gracies JM. Pathophysiology of spastic paresis. I: Paresis and soft tissue changes. Muscle Nerve. 2005;31(5):535\u201351. https:\/\/doi.org\/10.1002\/mus.20284.","journal-title":"Muscle Nerve"},{"issue":"3","key":"798_CR24","doi-asserted-by":"publisher","first-page":"193","DOI":"10.2340\/16501977-2211","volume":"49","author":"P Ertzgaard","year":"2017","unstructured":"Ertzgaard P, Campo C, Calabrese A. Efficacy and safety of oral baclofen in the management of spasticity: a rationale for intrathecal baclofen. J Rehabil Med. 2017;49(3):193\u2013203. https:\/\/doi.org\/10.2340\/16501977-2211.","journal-title":"J Rehabil Med"},{"key":"798_CR25","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2025.115730","author":"E Kussick","year":"2025","unstructured":"Kussick E, et al. Enhancer AAVs for targeting spinal motor neurons and descending motor pathways in rodents and macaque. Cell Rep. 2025. https:\/\/doi.org\/10.1016\/j.celrep.2025.115730.","journal-title":"Cell Rep"},{"issue":"12","key":"798_CR26","doi-asserted-by":"publisher","first-page":"5163","DOI":"10.1073\/pnas.0700293104","volume":"104","author":"BN Armbruster","year":"2007","unstructured":"Armbruster BN, et al. Evolving the lock to fit the key to create a family of G protein-coupled receptors potently activated by an inert ligand. Proc Natl Acad Sci USA. 2007;104(12):5163\u20138. https:\/\/doi.org\/10.1073\/pnas.0700293104.","journal-title":"Proc Natl Acad Sci USA"},{"key":"798_CR27","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2020.113889","volume":"175","author":"O Keifer","year":"2020","unstructured":"Keifer O, et al. Chemogenetics a robust approach to pharmacology and gene therapy. Biochem Pharmacol. 2020;175: 113889. https:\/\/doi.org\/10.1016\/j.bcp.2020.113889.","journal-title":"Biochem Pharmacol"},{"issue":"12","key":"798_CR28","doi-asserted-by":"publisher","first-page":"3484","DOI":"10.1016\/j.ymthe.2021.04.021","volume":"29","author":"PH Roseboom","year":"2021","unstructured":"Roseboom PH, et al. Evidence in primates supporting the use of chemogenetics for the treatment of human refractory neuropsychiatric disorders. Mol Ther. 2021;29(12):3484\u201397. https:\/\/doi.org\/10.1016\/j.ymthe.2021.04.021.","journal-title":"Mol Ther"},{"issue":"7","key":"798_CR29","doi-asserted-by":"publisher","first-page":"2192","DOI":"10.1111\/ejn.14746","volume":"53","author":"M Deffains","year":"2021","unstructured":"Deffains M, et al. In vivo electrophysiological validation of DREADD-based modulation of pallidal neurons in the non-human primate. Eur J Neurosci. 2021;53(7):2192\u2013204. https:\/\/doi.org\/10.1111\/ejn.14746.","journal-title":"Eur J Neurosci"},{"issue":"7245","key":"798_CR30","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1038\/nature08144","volume":"459","author":"DM Rosenbaum","year":"2009","unstructured":"Rosenbaum DM, Rasmussen SG, Kobilka BK. The structure and function of G-protein-coupled receptors. Nature. 2009;459(7245):356\u201363. https:\/\/doi.org\/10.1038\/nature08144.","journal-title":"Nature"},{"issue":"4","key":"798_CR31","doi-asserted-by":"publisher","first-page":"936","DOI":"10.1016\/j.neuron.2015.03.065","volume":"86","author":"E Vardy","year":"2015","unstructured":"Vardy E, et al. A new DREADD facilitates the multiplexed chemogenetic interrogation of behavior. Neuron. 2015;86(4):936\u201346. https:\/\/doi.org\/10.1016\/j.neuron.2015.03.065.","journal-title":"Neuron"},{"key":"798_CR32","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1007\/978-1-4939-9065-8_4","volume":"1937","author":"P Aldrin-Kirk","year":"2019","unstructured":"Aldrin-Kirk P, Bjorklund T. Practical considerations for the use of DREADD and other chemogenetic receptors to regulate neuronal activity in the mammalian brain. Methods Mol Biol. 2019;1937:59\u201387. https:\/\/doi.org\/10.1007\/978-1-4939-9065-8_4.","journal-title":"Methods Mol Biol"},{"issue":"6350","key":"798_CR33","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1126\/science.aan2475","volume":"357","author":"JL Gomez","year":"2017","unstructured":"Gomez JL, et al. Chemogenetics revealed: DREADD occupancy and activation via converted clozapine. Science. 2017;357(6350):503\u20137. https:\/\/doi.org\/10.1126\/science.aan2475.","journal-title":"Science"},{"issue":"5","key":"798_CR34","doi-asserted-by":"publisher","first-page":"ENEURO.0219-16","DOI":"10.1523\/eneuro.0219-16.2016","volume":"3","author":"DAA Maclaren","year":"2016","unstructured":"Maclaren DAA, et al. Clozapine N-oxide administration produces behavioral effects in long-evans rats: implications for designing DREADD experiments. Eneuro. 2016;3(5):ENEURO.0219-16. https:\/\/doi.org\/10.1523\/eneuro.0219-16.2016.","journal-title":"Eneuro"},{"key":"798_CR35","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-019-41088-2","author":"M Jendryka","year":"2019","unstructured":"Jendryka M, et al. Pharmacokinetic and pharmacodynamic actions of clozapine-N-oxide, clozapine, and compound 21 in DREADD-based chemogenetics in mice. Sci Reports. 2019. https:\/\/doi.org\/10.1038\/s41598-019-41088-2.","journal-title":"Sci Reports"},{"issue":"9","key":"798_CR36","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.1038\/s41593-020-0661-3","volume":"23","author":"Y Nagai","year":"2020","unstructured":"Nagai Y, et al. Deschloroclozapine, a potent and selective chemogenetic actuator enables rapid neuronal and behavioral modulations in mice and monkeys. Nat Neurosci. 2020;23(9):1157\u201367. https:\/\/doi.org\/10.1038\/s41593-020-0661-3.","journal-title":"Nat Neurosci"},{"issue":"4","key":"798_CR37","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1016\/j.neuron.2016.01.040","volume":"89","author":"BL Roth","year":"2016","unstructured":"Roth BL. DREADDs for neuroscientists. Neuron. 2016;89(4):683\u201394. https:\/\/doi.org\/10.1016\/j.neuron.2016.01.040.","journal-title":"Neuron"},{"issue":"2","key":"798_CR38","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1037\/bne0000135","volume":"130","author":"KS Smith","year":"2016","unstructured":"Smith KS, et al. DREADDS: use and application in behavioral neuroscience. Behav Neurosci. 2016;130(2):137\u201355. https:\/\/doi.org\/10.1037\/bne0000135.","journal-title":"Behav Neurosci"},{"key":"798_CR39","doi-asserted-by":"publisher","DOI":"10.3390\/cells11142236","author":"S Mun","year":"2022","unstructured":"Mun S, Han K, Hyun JK. The time sequence of gene expression changes after spinal cord injury. Cells. 2022. https:\/\/doi.org\/10.3390\/cells11142236.","journal-title":"Cells"},{"issue":"20","key":"798_CR40","doi-asserted-by":"publisher","first-page":"14890","DOI":"10.1074\/jbc.M110.107789","volume":"285","author":"T Lynagh","year":"2010","unstructured":"Lynagh T, Lynch JW. An improved ivermectin-activated chloride channel receptor for inhibiting electrical activity in defined neuronal populations. J Biol Chem. 2010;285(20):14890\u20137. https:\/\/doi.org\/10.1074\/jbc.M110.107789.","journal-title":"J Biol Chem"},{"key":"798_CR41","doi-asserted-by":"publisher","first-page":"75","DOI":"10.3389\/fnmol.2016.00075","volume":"9","author":"HA Obenhaus","year":"2016","unstructured":"Obenhaus HA, et al. Causal interrogation of neuronal networks and behavior through virally transduced ivermectin receptors. Front Mol Neurosci. 2016;9:75. https:\/\/doi.org\/10.3389\/fnmol.2016.00075.","journal-title":"Front Mol Neurosci"},{"issue":"29","key":"798_CR42","doi-asserted-by":"publisher","first-page":"21029","DOI":"10.1074\/jbc.M112.423921","volume":"288","author":"SJ Frazier","year":"2013","unstructured":"Frazier SJ, Cohen BN, Lester HA. An engineered glutamate-gated chloride (GluCl) channel for sensitive, consistent neuronal silencing by ivermectin. J Biol Chem. 2013;288(29):21029\u201342. https:\/\/doi.org\/10.1074\/jbc.M112.423921.","journal-title":"J Biol Chem"},{"issue":"Suppl 1","key":"798_CR43","doi-asserted-by":"publisher","first-page":"S215","DOI":"10.33549\/physiolres.932711","volume":"63","author":"H Zemkova","year":"2014","unstructured":"Zemkova H, et al. Allosteric modulation of ligand gated ion channels by ivermectin. Physiol Res. 2014;63(Suppl 1):S215\u201324.","journal-title":"Physiol Res"},{"key":"798_CR44","doi-asserted-by":"publisher","DOI":"10.1126\/science.aav5282","author":"CJ Magnus","year":"2019","unstructured":"Magnus CJ, et al. Ultrapotent chemogenetics for research and potential clinical applications. Science. 2019. https:\/\/doi.org\/10.1126\/science.aav5282.","journal-title":"Science"},{"issue":"50","key":"798_CR45","doi-asserted-by":"publisher","first-page":"18207","DOI":"10.1073\/pnas.0509024102","volume":"102","author":"T Grutter","year":"2005","unstructured":"Grutter T, et al. Molecular tuning of fast gating in pentameric ligand-gated ion channels. Proc Natl Acad Sci USA. 2005;102(50):18207\u201312. https:\/\/doi.org\/10.1073\/pnas.0509024102.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"1","key":"798_CR46","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1038\/s41467-024-44853-8","volume":"15","author":"QA Nguyen","year":"2024","unstructured":"Nguyen QA, et al. Acetylcholine receptor based chemogenetics engineered for neuronal inhibition and seizure control assessed in mice. Nat Commun. 2024;15(1):601. https:\/\/doi.org\/10.1038\/s41467-024-44853-8.","journal-title":"Nat Commun"},{"issue":"1","key":"798_CR47","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1038\/nbt.1515","volume":"27","author":"KD Foust","year":"2009","unstructured":"Foust KD, et al. Intravascular AAV9 preferentially targets neonatal neurons and adult astrocytes. Nat Biotechnol. 2009;27(1):59\u201365. https:\/\/doi.org\/10.1038\/nbt.1515.","journal-title":"Nat Biotechnol"},{"issue":"8","key":"798_CR48","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1089\/hum.1998.9.8-1181","volume":"9","author":"JS Bartlett","year":"1998","unstructured":"Bartlett JS, Samulski RJ, McCown TJ. Selective and rapid uptake of adeno-associated virus type 2 in brain. Hum Gene Ther. 1998;9(8):1181\u20136. https:\/\/doi.org\/10.1089\/hum.1998.9.8-1181.","journal-title":"Hum Gene Ther"},{"key":"798_CR49","doi-asserted-by":"publisher","DOI":"10.3389\/fnmol.2020.00076","author":"A-C Martel","year":"2020","unstructured":"Martel A-C, et al. Targeted transgene expression in cholinergic interneurons in the monkey striatum using canine adenovirus serotype 2 vectors. Front Mol Neurosci. 2020. https:\/\/doi.org\/10.3389\/fnmol.2020.00076.","journal-title":"Front Mol Neurosci"},{"key":"798_CR50","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1016\/j.omtm.2023.05.001","volume":"29","author":"MC Santoscoy","year":"2023","unstructured":"Santoscoy MC, et al. An AAV capsid increases transduction of striatum and a ChAT promoter allows selective cholinergic neuron transduction. Mol Ther Methods Clin Dev. 2023;29:532\u201340. https:\/\/doi.org\/10.1016\/j.omtm.2023.05.001.","journal-title":"Mol Ther Methods Clin Dev"},{"issue":"2","key":"798_CR51","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1089\/humc.2017.010","volume":"28","author":"Y Sehara","year":"2017","unstructured":"Sehara Y, et al. Persistent expression of dopamine-synthesizing enzymes 15 years after gene transfer in a primate model of Parkinson\u2019s disease. Hum Gene Ther Clin Dev. 2017;28(2):74\u20139. https:\/\/doi.org\/10.1089\/humc.2017.010.","journal-title":"Hum Gene Ther Clin Dev"},{"key":"798_CR52","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1016\/j.omtm.2021.09.017","volume":"23","author":"S Marco","year":"2021","unstructured":"Marco S, et al. Seven-year follow-up of durability and safety of AAV CNS gene therapy for a lysosomal storage disorder in a large animal. Mol Ther Methods Clin Dev. 2021;23:370\u201389. https:\/\/doi.org\/10.1016\/j.omtm.2021.09.017.","journal-title":"Mol Ther Methods Clin Dev"},{"issue":"4","key":"798_CR53","doi-asserted-by":"publisher","first-page":"1364","DOI":"10.1016\/j.ymthe.2022.03.004","volume":"30","author":"M Muhuri","year":"2022","unstructured":"Muhuri M, et al. Durability of transgene expression after rAAV gene therapy. Mol Ther. 2022;30(4):1364\u201380. https:\/\/doi.org\/10.1016\/j.ymthe.2022.03.004.","journal-title":"Mol Ther"},{"key":"798_CR54","doi-asserted-by":"crossref","unstructured":"Nagai Y et al. Longitudinal assessment of DREADD expression and efficacy in the monkey brain. 2025, eLife Sciences Publications, Ltd.","DOI":"10.7554\/eLife.105815.1"},{"issue":"1","key":"798_CR55","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1159\/000448765","volume":"95","author":"JJ Lamanna","year":"2017","unstructured":"Lamanna JJ, et al. Magnetic resonance imaging-guided transplantation of neural stem cells into the porcine spinal cord. Stereotact Funct Neurosurg. 2017;95(1):60\u20138. https:\/\/doi.org\/10.1159\/000448765.","journal-title":"Stereotact Funct Neurosurg"},{"key":"798_CR56","unstructured":"FDA Approves First Gene Therapy for Treatment of Aromatic L-amino Acid Decarboxylase Deficiency. 2024. fda.gov."},{"issue":"1","key":"798_CR57","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1038\/s41392-024-01780-w","volume":"9","author":"JH Wang","year":"2024","unstructured":"Wang JH, et al. Adeno-associated virus as a delivery vector for gene therapy of human diseases. Signal Transduct Target Ther. 2024;9(1):78. https:\/\/doi.org\/10.1038\/s41392-024-01780-w.","journal-title":"Signal Transduct Target Ther"},{"issue":"7","key":"798_CR58","doi-asserted-by":"publisher","first-page":"1529","DOI":"10.1038\/s41375-018-0106-0","volume":"32","author":"MC Milone","year":"2018","unstructured":"Milone MC, O\u2019Doherty U. Clinical use of lentiviral vectors. Leukemia. 2018;32(7):1529\u201341. https:\/\/doi.org\/10.1038\/s41375-018-0106-0.","journal-title":"Leukemia"}],"container-title":["Molecular Diagnosis & Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40291-025-00798-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40291-025-00798-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40291-025-00798-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,15]],"date-time":"2025-09-15T20:03:05Z","timestamp":1757966585000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40291-025-00798-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,30]]},"references-count":58,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["798"],"URL":"https:\/\/doi.org\/10.1007\/s40291-025-00798-2","relation":{},"ISSN":["1177-1062","1179-2000"],"issn-type":[{"type":"print","value":"1177-1062"},{"type":"electronic","value":"1179-2000"}],"subject":[],"published":{"date-parts":[[2025,7,30]]},"assertion":[{"value":"18 June 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 July 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Nicholas Boulis is an inventor on patents on technologies used to perform spinal cord injections that could be used to deliver chemogenetic vectors in the clinic (US 20100030184 A1; US 20160074119 A1). Anthony Donsante, Kelly Poth, and Roy Raheb Khelo have no interests to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests\/conflicts of interest"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for participation and publication"}},{"value":"Nicholas Boulis conceived the idea. Anthony Donsante, Kelly Poth, and Roy Raheb Khelo wrote portions of the initial draft. All authors reviewed and edited the initial draft and approved the final draft.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors\u2019 contributions"}},{"value":"Data sharing is not applicable to this article as no datasets were generated or analyzed during the current study.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data availability statement"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"No funding was received to assist with the preparation of this article.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}}]}}